Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J.C. Villasboas

The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas

Hematological Oncology

English

Related publications

Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease

Hematological Oncology

English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology

Hematology

2018

English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Hematological Oncology

English

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Journal of Clinical Oncology

English

A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B- Or T-Cell Lymphomas-The P[r]eben Study

Hematological Oncology

English

Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study

Hematological Oncology

English

Molecular Genetics of Aggressive B-Cell Lymphoma

Hematological Oncology

English

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Hematological Oncology

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J.C. Villasboas

The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas

Related publications

Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B- Or T-Cell Lymphomas-The P[r]eben Study

Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study

Molecular Genetics of Aggressive B-Cell Lymphoma

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA